HYBRID EVENT: Join us in person in Tokyo, Japan or attend virtually from anywhere.
Kupffer Cell Sarcoma

Kupffer cell sarcoma is a rare form of cancer that originates in the liver's Kupffer cells, specialized macrophages responsible for filtering and clearing foreign substances from the blood. This malignancy is categorized as a hepatic sarcoma, representing a small percentage of primary liver tumors. The etiology of Kupffer cell sarcoma remains unclear, and its occurrence is infrequent, making it challenging to study comprehensively. Diagnosing this sarcoma often involves a combination of imaging techniques, histopathological examination, and immunohistochemical analyses to identify specific markers associated with Kupffer cells. Symptoms may vary, and patients may present with nonspecific signs such as abdominal pain, weight loss, or fatigue. Due to the lack of distinctive clinical features, accurate diagnosis can be challenging, and Kupffer cell sarcoma may be mistaken for other hepatic lesions. Treatment options for Kupffer cell sarcoma typically include surgical resection when feasible, though the rarity of this cancer limits the development of standardized therapeutic approaches. The role of adjuvant therapies like chemotherapy or radiation remains uncertain, and their efficacy is not well-established. Prognosis for Kupffer cell sarcoma is generally poor due to the aggressive nature of the disease and the lack of specific treatment modalities. The rarity of this malignancy hampers the development of dedicated research efforts and comprehensive clinical trials, leaving healthcare professionals with limited evidence-based guidelines for managing affected individuals. In conclusion, Kupffer cell sarcoma poses a significant challenge in terms of diagnosis and treatment due to its rarity and lack of well-defined clinical characteristics. Further research is essential to enhance our understanding of this malignancy and to develop more effective therapeutic strategies for patients facing this rare form of liver cancer.

Committee Members
Speaker at International Conference on Clinical & Translational Oncology 2026 - Yan Leyfman

Yan Leyfman

NYP- Meyer Cancer Center, United States
Speaker at International Conference on Clinical & Translational Oncology 2026 - Rajvir Dahiya

Rajvir Dahiya

University of California San Francisco, United States
Speaker at International Conference on Clinical & Translational Oncology 2026 - Jianhua Luo

Jianhua Luo

University of Pittsburgh School of Medicine, United States
ICTO 2026 Speakers
Speaker at International Conference on Clinical & Translational Oncology 2026 - Pietro Salvatori

Pietro Salvatori

Formerly, Humanitas San Pio X Hospital, Italy
Speaker at International Conference on Clinical & Translational Oncology 2026 - Sergey Suchkov

Sergey Suchkov

N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Speaker at International Conference on Clinical & Translational Oncology 2026 - Shinya Tajima

Shinya Tajima

National Hospital Organization Shizuoka Medical Centre, Japan
Speaker at International Conference on Clinical & Translational Oncology 2026 - Nayara Delgado Andre

Nayara Delgado Andre

Federal University of São João del-Rei (UFSJ), Brazil

Submit your abstract Today

Facebook Twitter XTwitter Youtube
Watsapp